Fate Therapeutics Announces Leadership Transition; Scott Wolchko To Retire As President And CEO, Bob Valamehr To Become President And CEO January 1, 2025
Fate Therapeutics Announces Leadership Transition; Scott Wolchko To Retire As President And CEO, Bob Valamehr To Become President And CEO January 1, 2025
Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025
Bob Valamehr博士MBA将于2025年1月1日担任总裁兼首席执行官
Scott Wolchko To Retire as President and CEO after 10 years of Leadership in Pioneering iPSC-derived Cellular Immunotherapies
Scott Wolchko将在开拓性iPSC衍生细胞免疫疗法领域领导10年后退休
SAN DIEGO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE) ("Fate Therapeutics" or the "Company"), a clinical-stage biopharmaceutical company dedicated to bringing first-in-class induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that Scott Wolchko, the Company's President and CEO, will retire effective December 31, 2024. Fate's current President of Research and Development (R&D), Bob Valamehr, Ph.D. MBA, will assume the role of President and CEO as of January 1, 2025. Fate Therapeutics will passionately continue its mission to develop novel off-the-shelf cellular immunotherapies to broadly treat patients in need.
圣地亚哥，2024年11月29日（纳斯达克：FATE）（“Fate Therapeutics”或“公司”）——致力于为患癌症和自身免疫性疾病患者带来首创的诱导型多能干细胞（iPSC）衍生细胞免疫治疗方案的临床阶段生物制药公司Fate Therapeutics, Inc.今天宣布，该公司总裁兼首席执行官Scott Wolchko将于2024年12月31日生效退休。Fate现任研发总裁Bob Valamehr博士MBA将于2025年1月1日接任总裁兼首席执行官一职。Fate Therapeutics将激情地继续其使命，开发新型的现货细胞免疫治疗方案，广泛治疗有需要的患者。
